Original language | English |
---|---|
Journal | Journal of Clinical Oncology |
Volume | 29 |
Issue number | 15 |
Publication status | Published - 20 May 2011 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II. / Chau, I.; Okines, A.F.C.; de Castro, D.G.; Saffery, C.; Barbachano, Y.; Wotherspoon, A.; Puckey, L.; Wilson, S.H.; Coxon, F.Y.; Middleton, G.W.; Ferry, D.R.; Crosby, T.D.L.; Madhusudan, S.; Wadsley, J.; Waters, J.S.; Hall, M.; Swinson, D.; Robinson, A.; Smith, D.; Cunningham, D.; Gastro, U.K.N.C.R.I.U.
In: Journal of Clinical Oncology, Vol. 29, No. 15, 20.05.2011.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.
AU - Chau, I.
AU - Okines, A.F.C.
AU - de Castro, D.G.
AU - Saffery, C.
AU - Barbachano, Y.
AU - Wotherspoon, A.
AU - Puckey, L.
AU - Wilson, S.H.
AU - Coxon, F.Y.
AU - Middleton, G.W.
AU - Ferry, D.R.
AU - Crosby, T.D.L.
AU - Madhusudan, S.
AU - Wadsley, J.
AU - Waters, J.S.
AU - Hall, M.
AU - Swinson, D.
AU - Robinson, A.
AU - Smith, D.
AU - Cunningham, D.
AU - Gastro, U.K.N.C.R.I.U.
PY - 2011/5/20
Y1 - 2011/5/20
M3 - Article
VL - 29
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 15
ER -